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2 
Abstract 21 
The purpose of this study was to better understand the dissolution properties and 22 
precipitation behaviour of pharmaceutical cocrystals of poorly soluble drugs for the 23 
potential for oral administration based on a small scale dissolution assay. 24 
Carbamazepine and Indomethacin cocrystals with saccharin and nicotinamide as 25 
coformers were prepared with the sonic slurry method. Dissolution of the poorly soluble 26 
drugs indomethacin and carbamazepine and their cocrystals, was studied with a small 27 
scale dissolution assay installed on a SiriusT3 instrument. Two methodologies were 28 
used: i.) surface dissolution of pressed tablet (3mm) in 20mL running for fixed times at 29 
four pH stages (pH1.8, pH3.9, pH5.4, pH7.3), and ii.) powder dissolution (2.6 mg) in 30 
2mL at a constant pH (pH2). Improved dissolution and useful insights into precipitation 31 
kinetics of poorly soluble compounds from the cocrystal form can be revealed by the 32 
small scale dissolution assay. A clear difference in dissolution/precipitation behaviour 33 
can be observed based on the characteristics of the coformer used. 34 
 35 
Keywords indomethacin; carbamazepine; cocrystal; small-scale dissolution; precipitation 36 
37 
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INTRODUCTION 38 
Poor solubility is a major issue for the development of new compounds as it can impact on the 39 
bioavailability. Several strategies have been developed in order to improve solubility and the 40 
cocrystal strategy is one of them (1, 2). Cocrystals are crystalline materials comprising of at 41 
least two different components but the exact definition has created a lot of discussion in the 42 
literature related mainly to the properties of these components (3-6). According to the FDA, 43 
cocrystals are defined as, “solids that are crystalline materials composed of two or more 44 
molecules in the same crystal lattice” (7). Various approaches have been described in the 45 
literature for obtaining cocrystals, such as solution evaporation, mechanical grinding, melt 46 
extrusion, slurry and melt crystallization (5, 8, 9). 47 
The differences in molecular arrangements and solid-state thermodynamics can lead to 48 
significant changes in physicochemical and pharmacokinetic (PK) properties (10). Cocrystals 49 
can significantly increase the bioavailability of poorly soluble compounds based on limited 50 
animal bioavailability studies (11-14), but it should be noted that up to now, there are no human 51 
bioavailability studies available to validate the cocrystal effect on human pharmacokinetics. 52 
Some general conclusions concerning cocrystal effects on pharmacokinetics can be revealed 53 
by an analysis performed by Shan et al (10) based on animal data from 64 cocrystals involving 54 
21 APIs, with 80% of the studied APIs from BCS class II (10). Qualitative analysis between 55 
PK and solubility data of cocrystals led to a relatively strong positive correlation between AUC 56 
and solubility and to a strong negative correlation between solubility and Tmax for highly 57 
permeable APIs. Interestingly, cocrystallization might not only impact drug absorption, but 58 
also change other aspects of drug pharmacokinetics such as changes of drug distribution, 59 
metabolism and excretion especially when a biologically active coformer is used (10).  60 
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The physical and chemical properties of cocrystals have been extensively investigated (4). The 61 
selection of the coformer is a key issue and prediction of the crystal structure based solely on 62 
the molecular structure of a compound remains a challenge (10). Depending on the choice of 63 
coformer, the API solubility enhancement from the cocrystal may vary considerably, from less 64 
than 1 to values in excess of 100 fold (2).  65 
Dissolution testing can play an important role in several areas of drug development as a quality 66 
control tool and as an in vitro surrogate for in vivo performance. Most of the published 67 
dissolution studies with cocrystals have been reviewed by Thakuria et al 2013 (5). These are 68 
mainly studies of intrinsic dissolution rates measured in simple buffers or in biorelevant media 69 
and estimated on the basis of their individual molar extinction coefficients in the respective 70 
medium, with the use of simple set ups or compendial apparatus (i.e. USP Apparatus 2) (15-71 
18).  72 
Experimental dissolution data for cocrystals would represent many complex processes 73 
occurring simultaneously, such as the change of the solid form and of the surface area of the 74 
particles as cocrystals undergo solution-mediated phase transformation (8, 19). The 75 
relationship between the transformation rate and the dissolution rate is critical (15). The 76 
increase of the solubility of an API as a result of cocrystal formation often leads to 77 
transformation back into the pure API. In the case where the solubility of the cocrystal is higher 78 
than the solubility of the API, and the coformer and the API dissociate completely in solution, 79 
dissolution will lead to a supersaturated solution with the likelihood of API precipitation (6). 80 
An appropriately designed dissolution experiment would provide useful information relevant 81 
to the transformation of cocrystals and the absorption of the API. The importance of 82 
experimental set up and type of coformer for the enhanced dissolution properties of cocrystals 83 
was demonstrated for carbamazepine cocrystals (9). The use of an open system (flow-through 84 
cell apparatus) and media with a physiologically relevant amount of surfactant provided a 85 
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discriminatory dissolution method for the cocrystals, driven by the characteristics of the 86 
coformer used. Additionally, there has been a trend towards using novel low volume 87 
dissolution assays that are API sparing and can help with early development stage decisions 88 
for candidate progression. The European Union funded OrBiTo (Oral Biopharmaceutics Tools) 89 
project highlights such an initiative and brings together academia and industry in an attempt to 90 
develop new in-vivo predictive dissolution methodologies (20). 91 
In this paper, we describe small-scale disk and powder dissolution assays that can be used to 92 
assess cocrystal behaviour. As well as using only small quantities of material, a feature of these 93 
experiments is the capability to directly control and change pH in-situ which reveals interesting 94 
features with respect to dissolution and re-precipitation of the parent drug.  95 
Indomethacin and carbamazepine were selected as the model compounds. They are classified 96 
as BCS Class II compounds with low aqueous solubility. Saccharin (SAC; sulphonic acid 97 
derivative pKa = 1.2) and Nicotinamide (NIC; pKa 3.3) were the coformers selected for this 98 
study. Cocrystals were prepared using the sonic slurry method (9, 21).  99 
 100 
MATERIALS AND METHODS 101 
Materials 102 
Sodium dihydrogen phosphate and hydrochloric acid were purchased from Sigma-Aldrich, 103 
UK, sodium acetate was purchased from Fisher Scientific, UK, and potassium chloride was 104 
obtained from SureChem Ltd., UK. These reagents were used to prepare the dissolution 105 
medium. Potassium hydroxide (Fisher Scientific) was used to adjust pH in the disk dissolution 106 
assays. 107 
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Carbamazepine (99%) and saccharin (>98%) were purchased from Acros Organics and 108 
indomethacin and nicotinamide were purchased from Sigma-Aldrich. Indomethacin and 109 
carbamazepine cocrystals with saccharin and nicotinamide as coformers on a 1:1 molar ratio 110 
were prepared at Prosonix using the sonic slurry method whereby both API and coformer were 111 
introduced into an antisolvent and ultrasound applied. In summary, the API and the coformer 112 
were transferred to 400 mL ethyl acetate contained in a jacketed vessel with a side port for an 113 
ultrasound probe. The reaction temperature was maintained at ~15 °C and an ultrasound power 114 
of 30 W was applied. The slurry was stirred at a stirring rate of approximately 60 rpm and the 115 
resulting slurry was filtered. The resulting solid was dried under vacuum at 35°C overnight. 116 
The acoustic cavitation induces nucleation and crystallization leading to the formation of well 117 
defined co-crystals as physically characterized by scanning electron microscopy, differential 118 
scanning calorimetry, X-ray powder diffraction and particle size analysis (9, 22, 23). 119 
METHODS 120 
In vitro dissolution testing 121 
Dissolution of indomethacin and carbamazepine and the two cocrystals was studied at 25 oC 122 
with a small scale dissolution assay installed on a SiriusT3 instrument (Sirius Analytical 123 
Instruments, East Sussex, UK) (24) (Table 1). The SiriusT3 is an automatic titration system 124 
incorporating in-situ UV spectroscopy, which is specifically designed for the measurement of 125 
various physiochemical properties, including pKa, log P and solubility, as well as dissolution.  126 
The dissolution medium was prepared as 10mM phosphate and 10mM acetate pre-adjusted to 127 
a starting pH of 1.8 or pH 2 (using HCl) and in a background of 0.15M KCl. Potassium 128 
hydroxide was used to raise pH in the disk dissolution assays as described below. 129 
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Dissolution samples were used either directly as ~2.5mg powders or were prepared as tablets 130 
with a diameter of 3 mm, requiring approximate sample weights of 5 - 10 mg. This was 131 
carried out by using a modified Specac tablet press (Specac Ltd, Orpington, UK) 132 
incorporating a load cell for consistent pressure readings. The press is used with a set of 133 
tablet dies (3 mm diameter) to press a tablet of pure drug or cocrystal directly into a disc. 134 
Tablets were prepared using a 80 kg load force applied for a period of two minutes until the 135 
pressure readings remained constant, i.e., pressure readings reduce under initial compaction 136 
and so the force is increased again to maintain the 80 kg load. All tablets were then visually 137 
examined to ensure their surfaces were smooth and free of visible defects and the tablet discs 138 
were placed in tablet disc holders and held in situ by an O-ring seal, so that only one side of 139 
the tablet is exposed to the dissolution medium.   140 
The powder dissolution experiments consisted of 2 mL of the phosphate-acetate buffer 141 
medium adjusted to pH 2, to represent behavior at a gastric pH value, and added at the start of 142 
the dissolution experiment. For the tablets, 20mL of the phosphate-acetate dissolution 143 
medium was adjusted to pH 1.8 and added at the start of the dissolution experiment. The 144 
dissolution of the powders or tablets was directly monitored by multi-wavelength UV-145 
absorption spectroscopy using an in-situ fibre-optic UV probe (Figure 1). Dissolution data 146 
(UV spectra) were recorded for 240 minutes at pH 2, for the powders. For the tablets, 147 
dissolution data were recorded for 60 minutes at gastric pH 1.8, after which the pH was 148 
increased by dispensing KOH via a capillary, to simulate the pH transition occurring in the 149 
gastrointestinal tract. In the intestinal pH phase, KOH solution was added to raise the pH to 150 
3.9 and UV spectra were collected for a further 30 minutes. This process was continued 151 
stepwise by increasing the pH to 5.4 and 7.3 and collecting UV spectra for an additional 30 152 
minutes at each pH. Stirring of the solution was continuous and at a constant rate. After the 153 
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experiment, the UV absorption data were converted to an absolute sample weight using 154 
previously determined, pH-dependent, molar extinction coefficients. 155 
Molar extinction coefficients and pKas of the compounds were determined by UV-metric 156 
titration using the SiriusT3. The UV-metric method allowed the determination of molar 157 
extinction coefficients for neutral and ionised forms of a sample from a single experiment. 158 
Samples were typically prepared as 5 mM stock solutions in DMSO and titrated between pH 159 
2 and pH 12 in 1.5 mL of 0.15 M aqueous KCl. Sample concentrations were optimized in 160 
order to obtain a peak UV absorbance of approximately 1 absorbance unit.  161 
 162 
Table 1 here 163 
 164 
Dissolution profiles comparisons 165 
The difference between the mean dissolution data sets was assessed with the difference 166 
factor, f1 as described by Moore and Flanner (25). The difference factor was evaluated for the 167 
whole duration of the experiment (up to 4h). The dissolution data of the pure API were used as 168 
the reference data set when comparisons between the API and the cocrystal dissolution data set 169 
were performed, whereas the dissolution data of the saccharin cocrystal were used as the 170 
reference data set when comparisons between the dissolution performance of the two cocrystals 171 
were made. In the present study, a value of f1 higher than 15 was set as the limit for identifying 172 
differences between the samples. 173 
 174 
RESULTS 175 
 176 
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Indomethacin (IND) and its co-crystals (IND-SAC, IND-NIC) 177 
Surface dissolution of pressed tablet: The dissolution profile of the tablet of indomethacin 178 
shows that 4.0 ± 0.3 µg of API was released by the end of the first sector at pH 1.8. By 179 
comparison, 19 ± 3 µg of indomethacin was released from the indomethacin-saccharin 180 
cocrystal and 31 ± 7 µg from the indomethacin-nicotinamide co-crystal (Figure 2 and Table 2). 181 
By the end of the second sector, at pH 3.9, the amounts of dissolved indomethacin increased to 182 
5.1 ± 0.9, 25 ± 2 and 33 ± 6 µg for the IND, IND-SAC and IND-NIC respectively. When the 183 
pH of the dissolution medium rises above the pKa value (4.13) of indomethacin there was a 184 
significant increase in the amount of indomethacin released from both the tablets of the drug 185 
and of the cocrystals (21). The respective amounts dissolved at the end of the third sector (pH 186 
5.4) were 17 ± 3, 76 ± 14 and 61 ± 9 µg for the IND, IND-SAC and IND-NIC with the IND-187 
SAC showing the greatest amount released. At the end of the final pH sector (pH 7.4), the 188 
indomethacin-nicotinamide once again showed the greatest release with dissolved amounts of 189 
indomethacin at 141 ± 24, 549 ± 137 and 1327 ± 252 µg for the IND, IND-SAC and IND-NIC.     190 
 191 
Powder dissolution: The powder dissolution of all samples under constant pH (Figure 3 and 192 
Table 2) revealed the solubilisation enhancement of the drug from the cocrystal samples, and 193 
also provided information regarding the precipitation and kinetic solubility of the samples. 194 
Dissolution of indomethacin from the indomethacin-saccharin cocrystal was similar to the 195 
indomethacin-nicotinamide cocrystal reaching 26 ± 3 µg for IND-SAC versus 24 ± 1 µg for 196 
IND-NIC in the first three minutes. The onset of precipitation of the free indomethacin that 197 
was released at pH 2 occurred sooner for the indomethacin-saccharin cocrystal compared to 198 
the indomethacin-nicotinamide cocrystal. The amount of dissolved indomethacin released from 199 
the IND-SAC cocrystal peaked at 34 ± 2 µg after 7 minutes whilst it peaked at 45 ± 3 µg after 200 
13 minutes from the IND-NIC cocrystal. The final concentrations of dissolved indomethacin 201 
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at the end of the experiments was 19 ± 2 µg for IND-SAC and 14 ± 1 µg for IND-NIC 202 
suggesting that equilibrium solubility had been achieved for the precipitating form. By 203 
comparison, the amount of dissolved indomethacin from the pure API reached only 0.3 ± 0.1 204 
µg after 3 minutes and it was still dissolving by the end of the experiment where it had reached 205 
a level of 4.1 ± 0.3 µg after four hours. 206 
 207 
Table 2 here 208 
 209 
Carbamazepine (CBZ) and its cocrystals (CBZ-SAC, CBZ-NIC) 210 
Surface dissolution of pressed tablet: Dissolution profiles from the tablets of the drug and of 211 
the cocrystals (Figure 4 and Table 3) revealed some interesting behavior. The saccharin 212 
cocrystal had the highest solubilisation followed by carbamazepine API and then the 213 
nicotinamide cocrystal was the lowest. Also, there was little dependence on pH and the 214 
dissolution profiles showed a continual release, as one process, over all of the pH sectors. The 215 
amount of carbamazepine released from the pure drug was 368 ± 26 µg at the end of the first 216 
sector (pH 1.8), 429 ± 42 µg at the end of the second sector (pH 3.9), and 480 ± 61 µg and 519 217 
± 87 µg at the end of the third (pH 5.4) and fourth (pH 7.3) sectors. The corresponding amounts 218 
of released carbamazepine from the CBZ-NIC cocrystal were 215 ± 19 µg (pH 1.8), 261 ± 21 219 
µg (pH 3.9), 301 ± 26 µg (pH 5.4) and 340 ± 29 µg (pH 7.3) and from the CBZ-SAC cocrystal 220 
were 469 ± 28 µg (pH 1.8), 541 ± 26 µg (pH 3.9), 596 ± 26 µg (pH 5.4) and 642 ± 23 µg (pH 221 
7.3). Whilst carbamazepine itself is a non-ionisable compound both the coformers, 222 
nicotinamide and saccharin, are ionisable with pKa values, measured in this work, of 3.3 (basic) 223 
and 1.2 (acidic), respectively.    224 
 225 
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Powder dissolution: The powder dissolution of all samples under constant pH 2 revealed that 226 
carbamazepine dissolved much more slowly from the carbamazepine sample than from the 227 
cocrystal samples and also provided information regarding the precipitation and kinetic 228 
solubility of the samples (Figure 5 and Table 3). The amount of dissolved carbamazepine 229 
reached 152 ± 9 µg from the CBZ-NIC cocrystal and 114 ± 2 µg from the CBZ-SAC in the 230 
first 90 seconds whilst CBZ reached only 27 ± 4 µg in the same time. The samples continued 231 
to dissolve reaching peak concentrations of 197 ± 47 µg for CBZ-NIC after 2 minutes, 371 ± 232 
24 µg for CBZ-SAC after 11 minutes, and 370 ± 5 µg after 77 minutes for pure CBZ. The drop 233 
in concentration observed following dissolution of the pure CBZ is probably due to the 234 
formation of the less soluble carbamazepine dihydrate form (26). The concentration decreased 235 
to 285 ± 7 µg of dissolved carbamazepine by the end of the four hour experiment. Precipitation 236 
of carbamazepine from the CBZ-SAC cocrystal occurred at a much earlier time and the final 237 
dissolved concentration reached a similar level at 277 ± 10 µg after four hours. Dissolution of 238 
carbamazepine from the CBZ-NIC cocrystal was faster than from the CBZ-SAC cocrystal and 239 
produced a heavily turbid solution as the carbamazepine precipitated from solution after 2 240 
minutes. The final amount of dissolved carbamazepine from the CBZ-NIC experiments was 70 241 
± 27 µg after 130 minutes. 242 
 243 
Table 3 here 244 
 245 
DISCUSSION 246 
Small scale dissolution assays (24) can be used to illustrate the different behavior of the 247 
cocrystals (i) with respect to pressed tablet dissolution as a function of pH and (ii) solubilization 248 
capacity and precipitation behavior of powder samples at pH2. 249 
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 250 
For the dissolution of tablets, cocrystals with indomethacin dissolved faster than pure 251 
indomethacin, and the greatest solubilisation occurred, in all cases, above the pKa value (4.13) 252 
of indomethacin when it becomes negatively charged (Figure 2 and Table 2). A comparison of 253 
the tablet dissolution profiles provided f1 values of 283 and 618 for the IND-SAC tablet and 254 
the IND-NIC tablet, respectively when compared to the IND tablet. The dissolution profile of 255 
the IND-NIC tablet was substantially different than the dissolution profile of the IND-SAC 256 
tablet (f1 = 90). The tablets were prepared using an 80 kg load force applied for a period of two 257 
minutes until the pressure readings remained constant and all tablets were visually examined 258 
to ensure their surfaces were smooth and free of visible defects. It was therefore thought 259 
unlikely that the compaction force would have a strong influence on the differences observed 260 
between the dissolution profiles, as was demonstrated in a recent publication on tablet 261 
dissolution of indomethacin crystalline forms (27).   262 
Powder dissolution of pure indomethacin at pH 2 was very low for the duration of the assay 263 
reaching only 4 µg in the 2mL volume and showing the poor solubility of the free form of the 264 
API. The powders of the cocrystals had improved dissolution performance but precipitation 265 
could not be prevented as the solubility limit of indomethacin was soon exceeded as it was 266 
released from the cocrystal (Figure 3 and Table 2). Maximum solubilization from the IND-267 
SAC cocrystal was 17 µg/mL and from the IND-NIC cocrystal 23 µg/mL. After precipitation, 268 
both co-crystals reached a similar concentration of 7 µg/mL for IND-NIC and 8 µg/mL for 269 
IND-SAC after ~90 minutes but this was still much higher than the solubility of the crystalline 270 
form of indomethacin (2 µg/mL). A comparison of the powder dissolution profiles provided f1 271 
values of 627 and 554 for the IND-SAC powder sample and the IND-NIC powder sample, 272 
respectively when compared to the IND powder sample. The dissolution profile of the IND-273 
NIC powder sample was different than the dissolution profile of the IND-SAC tablet (f1 = 25). 274 
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 275 
Tablet dissolution of carbamazepine and its cocrystals showed similarly shaped release profiles 276 
for the amount of carbamazepine entering the solution (Figure 4 and Table 3). However, only 277 
the CBZ-SAC cocrystal provided enhanced solubilisation of carbamazepine whereas the CBZ-278 
NIC cocrystal showed much less carbamazepine going into solution and a slower dissolution 279 
rate, when compared to the pure carbamazepine. A comparison of the tablet dissolution profiles 280 
provided f1 values of 30 and 40 for the CBZ-SAC tablet and the CBZ-NIC tablet, respectively 281 
when compared to the CBZ tablet. The dissolution profile of the CBZ-NIC tablet was 282 
significantly different than the dissolution profile of the CBZ-SAC tablet (f1 = 54). In this case 283 
also, as for the indomethacin and the indomethacin cocrystal tablets, carbamazepine tablets and 284 
carbamazepine cocrystal tablets were prepared using an 80 kg load force applied for a period 285 
of two minutes until the pressure readings remained constant and all tablets were visually 286 
examined to ensure their surfaces were smooth and free of visible defects. It was also thought 287 
unlikely that the compaction force would have a strong influence on comparison of the release 288 
profiles. Thus, the substantial difference between the amounts dissolved from the cocrystals 289 
tablets and the API tablets at various time intervals (as indicated by the f1 values), can be 290 
attributed to the differences in the physicochemical properties of the samples tested.   291 
Powder dissolution of carbamazepine at pH 2 reached 185 µg/mL before precipitating after 77 292 
minutes. The precipitation event probably represents transformation to the less soluble 293 
dihydrate form (26). The powder of the CBZ-SAC cocrystal had a faster initial dissolution rate 294 
than the CBZ powder although the peak concentration was the same (186 µg/mL) and 295 
precipitation was observed at a much earlier time point (11 minutes). The final concentrations 296 
after 4 hours dissolution from the carbamazepine powder sample and the CBZ-SAC cocrystal 297 
powder sample were also similar at 143 µg/mL and 139 µg/mL (Figure 5 and Table 3). The 298 
initial dissolution of the CBZ-NIC cocrystal powder was rapid (76 µg/mL in the first 90 299 
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seconds) but precipitation occurred very quickly after 2 minutes and the peak concentration 300 
only reached 99 µg/mL. Following precipitation, the final concentration obtained was much 301 
lower at 35 µg/mL. A comparison of the powder dissolution profiles provided f1 values of 20 302 
and 78 for the CBZ-SAC powder sample and the CBZ-NIC powder sample, respectively when 303 
compared to the CBZ powder sample. The dissolution profile of the CBZ-NIC powder sample 304 
was significantly different than the dissolution profile of the CBZ-SAC powder sample (f1 = 305 
76). 306 
The powder results and tablet results for carbamazepine, on first appearances, seem to be 307 
showing different behavior to each other. The CBZ-NIC cocrystal dissolved so rapidly as a 308 
powder that it released free carbamazepine that precipitated almost immediately resulting in 309 
very poor solubility. The CBZ-NIC tablet dissolved slower by comparison but similarly it also 310 
ended up with the lowest amount of total dissolved carbamazepine. We hypothesize that as 311 
nicotinamide is released from the surface, insoluble carbamazepine is left behind and coats the 312 
surface of the tablet thus retarding further dissolution. Hence, for both the tablet and powder 313 
assays we ended up with the least amount of carbamazepine in solution from the CBZ-NIC 314 
cocrystal. In future studies, confirmation of form changes by analysis of the solid form 315 
remaining at the end of the experiment could provide a clear description of the product 316 
remaining after the dissolution. Additionally, the use of in-situ Raman technology, which is 317 
increasingly being used in tandem with small scale dissolution methodologies, would directly 318 
reveal the nature of such form changes as the experiment progresses (28). 319 
 320 
CONCLUSIONS  321 
Improved dissolution and useful insights into precipitation kinetics of poorly soluble 322 
compounds from the cocrystal form can be revealed by the small scale dissolution assay. A 323 
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clear difference in dissolution/precipitation behaviour can be observed based on the 324 
characteristics of the coformer used. An increase in dissolution of indomethacin and 325 
carbamazepine from cocrystals would lead to an expectation of increased oral absorption of 326 
these highly permeable BCS Class II compounds due to increased solubilisation. However, 327 
improved dissolution kinetics should be tempered against faster drug precipitation kinetics 328 
during selection of a coformer and a balance struck to achieve optimum performance.  329 
Small scale dissolution assays can be easily set up on the SiriusT3 to screen a selection of 330 
candidate cocrystals (or salts or polymorphs) during early development under a variety of 331 
conditions (powders, compacts, gastric and intestinal pH). 332 
Future work should be directed towards understanding the solid-state transformations and 333 
precipitation behavior in more detail and how this may impact on the oral absorption of the 334 
drugs. Additionally, understanding the impact of formulation additives such as polymeric 335 
precipitation inhibitors (polyvinylpyrrolidones or celluloses) would be valuable. 336 
  337 
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Table 1: Conditions of dissolution experiments. 429 
 430 
 431 
Experiment Dissolution 
Medium 
Sector 1 Sector 2 Sector 3 Sector 4 
Powder 
Dissolution 
10mM Phosphate 
buffer – 10mM 
acetate buffer 
adjusted to pH 2 
UV spectra 
recorded for 
240 minutes 
at pH 2 
n/a n/a n/a 
Pressed 
tablet 
Dissolution 
10mM Phosphate 
buffer – 10mM 
acetate buffer 
adjusted to pH 1.8 
UV spectra 
recorded for 
60 minutes 
at pH 1.8 
UV spectra 
recorded for 
30 minutes 
at pH 3.9* 
UV spectra 
recorded for 
60 minutes 
at pH 5.4* 
UV spectra 
recorded for 
60 minutes 
at pH 7.4* 
   * Sector pH reached by in-situ addition of KOH. 432 
 433 
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 435 
Table 2: Summary of tablet and powder dissolution results for indomethacin and its cocrystals 436 
(n=3). 437 
 438 
 439 
Amount Dissolved 
Indomethacin 
IND tablet*           
(µg) 
IND-SAC tablet* 
(µg) 
IND-NIC tablet* 
(µg) 
End of  Sector 1     
(pH 1.8) 
4.0 ± 0.3 19 ± 3 31 ± 7 
End of  Sector 2     
(pH 3.9) 
5.1 ± 0.9 25 ± 2 33 ± 6 
End of  Sector 3     
(pH 5.4) 
17 ± 3 76 ± 14  61 ± 9 
End of  Sector 4     
(pH 7.3) 
141 ± 24 549 ± 137 1327 ± 252 
 IND powder#      
(µg) 
IND-SAC powder#     
(µg) 
IND-NIC powder#     
(µg) 
After 3 minutes 0.3 ± 0.1 26 ± 3 24 ± 1 
Peak Concentration 
(time) 
4.1 ± 0.3            
(four hours) 
34 ± 2                     
(7 mins) 
45 ± 3                  
(13 mins) 
Final amount 4.1 ± 0.3             19 ± 2  14 ± 1 
* Experiments performed in 20mL volume. 440 
 # Experiments performed in 2mL volume at pH 2. 441 
 442 
  443 
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 444 
Table 3: Summary of tablet and powder dissolution results for carbamazepine and its cocrystals 445 
(n=3). 446 
 447 
 448 
Amount Dissolved 
Carbamazepine 
CBZ tablet*           
(µg) 
CBZ-SAC tablet* 
(µg) 
CBZ-NIC tablet* 
(µg) 
End of  Sector 1     
(pH 1.8) 
368 ± 26 469 ± 28 215 ± 19 
End of  Sector 2     
(pH 3.9) 
429 ± 42 541 ± 26 261 ± 21 
End of  Sector 3     
(pH 5.4) 
480 ± 61 596 ± 26 301 ± 26 
End of  Sector 4     
(pH 7.3) 
519 ± 87 642 ± 23 340 ± 29 
 CBZ powder#      
(µg) 
CBZ-SAC powder#     
(µg) 
CBZ-NIC powder#     
(µg) 
After 90 seconds 27 ± 4 114 ± 2 152 ± 9 
Peak Concentration 
(time) 
370 ± 5                 
(77 mins) 
371 ± 24                
(11 mins) 
197 ± 47                
(2 mins) 
Final amount 285 ± 7   277 ± 10 70 ± 27 
* Experiments performed in 20mL volume. 449 
 # Experiments performed in 2mL volume at pH 2. 450 
 451 
  452 
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 453 
LEGEND TO FIGURES  454 
Figure 1: Small scale dissolution assay (Sirius system) 455 
Figure2: Dissolution of indomethacin and cocrystal pressed tablets (n=3) over four pH sectors. 456 
Figure 3: Dissolution of indomethacin and cocrystal powders (n=3) at pH2. 457 
Figure 4: Dissolution of carbamazepine and cocrystal pressed tablets (n=3) over four pH 458 
sectors. 459 
Figure 5: Dissolution of carbamazepine and cocrystal powders (n=3) at pH2.  460 
 461 
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Figure 1: Small scale dissolution assay (Sirius system) 466 
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 469 
 470 
 471 
Figure 2: Dissolution of indomethacin and cocrystal pressed tablets (n=3) over four pH sectors. 472 
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Figure 3: Dissolution of indomethacin and cocrystal powders (n=3) at pH2. 477 
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Figure 4: Dissolution of carbamazepine and cocrystal pressed tablets (n=3) over four pH 482 
sectors. 483 
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Figure 5: Dissolution of carbamazepine and cocrystal powders (n=3) at pH2. 488 
 489 
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